{"id":56783,"date":"2026-02-10T22:27:00","date_gmt":"2026-02-10T14:27:00","guid":{"rendered":"https:\/\/flcube.com\/?p=56783"},"modified":"2026-02-10T22:27:01","modified_gmt":"2026-02-10T14:27:01","slug":"huadong-medicine-and-shian-biotech-advance-sirna-obesity-therapy-to-preclinical-stage","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56783","title":{"rendered":"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage"},"content":{"rendered":"\n<p><strong>Huadong Medicine Co., Ltd<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/000963:SHE\">SHE: 000963<\/a><\/strong>) announced a <strong>key milestone<\/strong> in its <strong>strategic collaboration<\/strong> with <strong>Suzhou Shian Biotechnology Co., Ltd.<\/strong>, advancing their <strong>jointly developed siRNA therapy<\/strong> for <strong>obesity and metabolic diseases<\/strong> into formal <strong>preclinical development<\/strong>. The partnership, established in <strong>early 2025<\/strong>, has successfully completed <strong>preclinical candidate compound (PCC) identification<\/strong> for a <strong>novel weight-loss mechanism<\/strong>, positioning the asset for <strong>IND-enabling studies<\/strong> and potential <strong>global licensing opportunities<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-milestone\">Partnership Structure &amp; Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Huadong Medicine (SHE: 000963) \u00d7 Suzhou Shian Biotechnology<\/td><\/tr><tr><td><strong>Partnership Inception<\/strong><\/td><td>Early 2025<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Obesity and non-alcoholic steatohepatitis (MASH)<\/td><\/tr><tr><td><strong>Modality<\/strong><\/td><td>siRNA (small interfering RNA) therapy<\/td><\/tr><tr><td><strong>Current Milestone<\/strong><\/td><td>Preclinical candidate compound (PCC) identified<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Formal preclinical research initiated<\/td><\/tr><tr><td><strong>Shian Economics<\/strong><\/td><td>Upfront payment, milestones, and substantial share of ex-territory licensing fees<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-strategic-rationale\">Technology Platform &amp; Strategic Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>siRNA Approach<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td>Novel weight-loss target via RNA interference<\/td><td>Differentiation from GLP-1 receptor agonist saturation<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td>Potential for <strong>quarterly or bi-annual dosing<\/strong> vs. weekly injections<\/td><td>Improved patient compliance, reduced healthcare burden<\/td><\/tr><tr><td><strong>MASH Synergy<\/strong><\/td><td>Dual metabolic\/liver benefit pathway<\/td><td>Addresses comorbidity of obesity and fatty liver disease<\/td><\/tr><tr><td><strong>Next-Generation Positioning<\/strong><\/td><td>Post-GLP-1 era innovation<\/td><td>Captures market seeking alternatives to incretin therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Collaboration Logic:<\/strong> Huadong Medicine contributes <strong>clinical development expertise, regulatory resources, and China commercial infrastructure<\/strong>; Shian Biotech provides <strong>proprietary siRNA platform and novel target biology<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Market Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Obesity Market<\/strong><\/td><td>Projected <strong>$100 billion by 2030<\/strong>; GLP-1 drugs (Ozempic, Wegovy) dominate but face adherence and muscle-loss challenges<\/td><\/tr><tr><td><strong>siRNA Metabolic Pipeline<\/strong><\/td><td>Emerging class with <strong>Arrowhead, Alnylam, and Ionis<\/strong> advancing candidates; first-mover advantage in specific targets critical<\/td><\/tr><tr><td><strong>China Obesity Burden<\/strong><\/td><td><strong>&gt;50% of adults overweight\/obese<\/strong>; domestic innovation prioritized under Healthy China 2030<\/td><\/tr><tr><td><strong>MASH Opportunity<\/strong><\/td><td><strong>$35 billion projected market<\/strong> with no approved pharmacotherapies; siRNA offers disease-modifying potential<\/td><\/tr><tr><td><strong>Licensing Potential<\/strong><\/td><td>Shian&#8217;s <strong>ex-territory fee structure<\/strong> indicates expectation of <strong>global Big Pharma partnership<\/strong> for US\/EU markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>PCC identified; preclinical studies initiated<\/td><td>Q1 2026<\/td><\/tr><tr><td><strong>Near-term<\/strong><\/td><td>IND-enabling toxicology, pharmacology, and manufacturing<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Clinical<\/strong><\/td><td>Phase I initiation (China)<\/td><td>2027<\/td><\/tr><tr><td><strong>Global<\/strong><\/td><td>US\/EU IND filing and partnership discussions<\/td><td>2027-2028<\/td><\/tr><tr><td><strong>Expansion<\/strong><\/td><td>MASH indication clinical validation<\/td><td>Parallel track<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding siRNA therapy development timelines, preclinical-to-clinical transition success, and global licensing outcomes for the Huadong-Shian collaboration. Actual results may differ due to siRNA delivery challenges (hepatotoxicity, off-target effects), competitive dynamics in the obesity drug market, and partnership negotiation results with multinational pharmaceutical companies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[114,64,887,4598],"class_list":["post-56783","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-drug","tag-huadong-medicine","tag-rnai-aso","tag-she-000963","tag-shian-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with Suzhou Shian Biotechnology Co., Ltd., advancing their jointly developed siRNA therapy for obesity and metabolic diseases into formal preclinical development. The partnership, established in early 2025, has successfully completed preclinical candidate compound (PCC) identification for a novel weight-loss mechanism, positioning the asset for IND-enabling studies and potential global licensing opportunities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56783\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage\" \/>\n<meta property=\"og:description\" content=\"Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with Suzhou Shian Biotechnology Co., Ltd., advancing their jointly developed siRNA therapy for obesity and metabolic diseases into formal preclinical development. The partnership, established in early 2025, has successfully completed preclinical candidate compound (PCC) identification for a novel weight-loss mechanism, positioning the asset for IND-enabling studies and potential global licensing opportunities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56783\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T14:27:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T14:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56783#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56783\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage\",\"datePublished\":\"2026-02-10T14:27:00+00:00\",\"dateModified\":\"2026-02-10T14:27:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56783\"},\"wordCount\":403,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Huadong Medicine\",\"RNAi \\\/ ASO\",\"SHE: 000963\",\"Shian Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56783#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56783\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56783\",\"name\":\"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-10T14:27:00+00:00\",\"dateModified\":\"2026-02-10T14:27:01+00:00\",\"description\":\"Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with Suzhou Shian Biotechnology Co., Ltd., advancing their jointly developed siRNA therapy for obesity and metabolic diseases into formal preclinical development. The partnership, established in early 2025, has successfully completed preclinical candidate compound (PCC) identification for a novel weight-loss mechanism, positioning the asset for IND-enabling studies and potential global licensing opportunities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56783#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56783\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56783#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage - Insight, China&#039;s Pharmaceutical Industry","description":"Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with Suzhou Shian Biotechnology Co., Ltd., advancing their jointly developed siRNA therapy for obesity and metabolic diseases into formal preclinical development. The partnership, established in early 2025, has successfully completed preclinical candidate compound (PCC) identification for a novel weight-loss mechanism, positioning the asset for IND-enabling studies and potential global licensing opportunities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56783","og_locale":"en_US","og_type":"article","og_title":"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage","og_description":"Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with Suzhou Shian Biotechnology Co., Ltd., advancing their jointly developed siRNA therapy for obesity and metabolic diseases into formal preclinical development. The partnership, established in early 2025, has successfully completed preclinical candidate compound (PCC) identification for a novel weight-loss mechanism, positioning the asset for IND-enabling studies and potential global licensing opportunities.","og_url":"https:\/\/flcube.com\/?p=56783","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-10T14:27:00+00:00","article_modified_time":"2026-02-10T14:27:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56783#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56783"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage","datePublished":"2026-02-10T14:27:00+00:00","dateModified":"2026-02-10T14:27:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56783"},"wordCount":403,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Huadong Medicine","RNAi \/ ASO","SHE: 000963","Shian Biotechnology"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56783#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56783","url":"https:\/\/flcube.com\/?p=56783","name":"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-10T14:27:00+00:00","dateModified":"2026-02-10T14:27:01+00:00","description":"Huadong Medicine Co., Ltd (SHE: 000963) announced a key milestone in its strategic collaboration with Suzhou Shian Biotechnology Co., Ltd., advancing their jointly developed siRNA therapy for obesity and metabolic diseases into formal preclinical development. The partnership, established in early 2025, has successfully completed preclinical candidate compound (PCC) identification for a novel weight-loss mechanism, positioning the asset for IND-enabling studies and potential global licensing opportunities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56783#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56783"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56783#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56783"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56783\/revisions"}],"predecessor-version":[{"id":56784,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56783\/revisions\/56784"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}